U.S. Markets open in 3 hrs 57 mins

Neurocrine Biosciences, Inc. (NBIX)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
52.15-0.97 (-1.83%)
At close: 4:00PM EDT
People also watch
ALKSLGNDPGNXNKTRMDCO
  • H
    Horowitz
    Horowitz

    SNOA (MC $23 M) (Cash $13 M) Shares Out: 4.3 M / 17 FDA approved products some of them are in early launch phase plus additional Product launches expected within 6 months / Profitable in 2018 = 1000%+ UPSIDE POTENTIAL..GLTA

    Sonoma Pharma (Nasdaq: SNOA)

    Market Cap: 22.1 Million
    Cash: $12.6 Million
    Price: $5.15

    Shares Out : 4.3 Million

    Presentation
    http://ir.sonomapharma.com/common/download/download.cfm?companyid=ocls&fileid=945547&filekey=F57B6874-6CD1-4205-A160-8E08BBB7A928&filename=SonomaPharma_Investor_presentation_13June2017.pdf

    Fact Sheet
    http://files.shareholder.com/downloads/OCLS/4977255852x0x231236/39d834a3-8462-40ee-8650-e0945b6facd5/Sonoma_Fact_Sheet.pdf

    Driving to commercial EBITDAS breakeven, without dilution

    Grow current product portfolio with all sales people

    •Alevicyn HydroGel, Dermal Spray & Spray Gel for atopic dermatitis & dermal procedures •Celacyn for scar treatment
    •Mondoxyne for severe acne –launched late 2015
    •Ceramax for skin repair in atopic dermatitis–launched in April 2016
    •SebuDerm for seborrhea dermatitis –launched in November 2016

    Launch 3 New Products –our product pipeline –one every other quarter

    •Launching Loyon–Fall 2017
    •Ceramax in foam and gel forms –Q4 2017 & Q1 2018

    Launch and Grow New and Current Products: During fiscal year 2017, we launched four new dermatology products, including SebuDerm™, Ceramax™, Lasercyn™ Gel and Lasercyn™ Dermal Spray, bringing us to a total of eight dermatology products for the treatment of atopic and seborrheic dermatitis, scar management, surgical procedures, severe acne and “state of the art” skin repair technology. We also obtained three new FDA clearances, now totaling 16 overall. Our strong intellectual property portfolio consists of 63 issued patents and 33 patent applications pending.

    We plan to launch our new FDA approved product Loyon® (a skin descaler currently marketed in Europe) in the upcoming months and have a strong product pipeline of several product line improvements, including a line extension of Ceramax™. All in all, we believe this could possibly be our best product line of new FDA approved dermatology and skincare products yet, and we believe our innovation plan will help lead us to profitability.

  • K
    Kaitlyn
    Kaitlyn
    The scenarios are quite interesting at current levels for NBIX. I started receiving notifications from Awe.Som.e.Sto-cks. the other week and so far they have presented interesting new trade ideas.
  • N
    Noellus
    Noellus
    Very solid balance sheet given their stage in the cycle.
    Whoever the acquirer turns out to be they'll have to pony up.
  • J
    Johnny
    Johnny
    U guys know what time it is. Short over $50, cover at $40.
  • N
    Noellus
    Noellus
    It's almost as if the market is finally, albeit grudgingly, accepting that Ingrezza is real!
  • M
    Matthew
    Matthew
    Had to sell this beginning of last week to cover a large cash out flow- kicking myself now!
  • S
    Surfin'
    Surfin'
    I sold my shares too early. I still like their prospects. Any advice re. a good re-entry point?
  • D
    Dennis
    Dennis
    Ave volume 1 million shares.. first 15 minutes after open.. half a million.. something is up!!
  • F
    Fredek
    Fredek
    Blggest M0vers in the NASDAQ, NYSE, and OTC Markets ---> PennyStOck1O1.org
  • B
    Baryram
    Baryram
    Blggest M0vers in the NASDAQ, NYSE, and OTC Markets ---> PennyStOck1O1.org
  • K
    King of Kings
    King of Kings
    I'm out. Will wait after the earnings.
  • t
    timothy m
    timothy m
    It will be nice to see this stock hit $50....But when it hits $60 BANG!
  • L
    Lisa
    Lisa

    http://jcharlesassets.com/opiant-pharmaceuticals/?s=NBIX has an alert for $NBIX. Did anyone happen to see it as well? Looking for some good positive information from the company! "rht" Making money trading stocks.

    Best MicroCap, Small Cap and Emerging Stocks to Buy - J Charles Assets
    We search for the smart new growing companies to invest in with stock deals to watch in pharmacuetical and digital verticals.
    jcharlesassets.com
  • M
    Matthew
    Matthew
    All aboard!
  • M
    Matthew
    Matthew
    would like to see this back above 50 bucks. it will get there.
  • S
    Shayla
    Shayla
    The upside potential for NBIX just got a whole lot more interesting. awe*some*stocks just allerted a new stock - it beats having to dig online yourself for new stock ideas.
  • H
    HotPicks
    HotPicks
    Like buying NBIX below $3 in 2010
    (AXSM) Mcap $90 M /Cash $55 M / 5x Phase 3 programs in various indications targeting huge Markets with first results in Q3 2017 =10+ BAGGER ....GLTA ! Please readand realize the brutal potential !

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $90 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $90 Million
    Cash: $55 Million(cash runway into the first quarter of 2019.)
    Price:$3.90

    Shares Out: 23.5 Million

    Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.
  • E
    Evelyn
    Evelyn

    Got a great report from http://jcharlesassets.com/opiant-pharmaceuticals/?s=NBIX about $NBIX. I did have to subscribe but it was worth the time. Thank you guys for the tip! "rht" Trading stocks investing.

    Best Penny, OTC Stocks and Dividend Stocks to Buy - J Charles Assets
    We search for the smart new growing companies to invest in with stock deals to watch in pharmacuetical and digital verticals.
    jcharlesassets.com
  • W
    Wolf of Windsor
    Wolf of Windsor
    Good chance we see 39 within the next 2 weeks, its a buy at that point boys, just hang on here.
  • W
    Wolf of Windsor
    Wolf of Windsor
    The Wolf has returned to pounce on nbix yet again!. Nbix is the gift that just keeps on giving, it gives me shares in the low 40s, then I sell it in the mid 50s!